| Literature DB >> 25692137 |
A Rizzo1, C Vasco1, V Girgenti1, V Fugnanesi2, C Calatozzolo2, A Canazza3, A Salmaggi4, L Rivoltini5, M Morbin2, E Ciusani1.
Abstract
We developed an in vitro contact through-feet blood brain barrier (BBB) model built using type IV collagen, rat astrocytes, and human umbilical vein endothelial cells (HUVECs) cocultured through Transwell porous polycarbonate membrane. The contact between astrocytes and HUVECs was demonstrated by electron microscopy: astrocytes endfeet pass through the 8.0 μm pores inducing HUVECs to assume a cerebral phenotype. Using this model we evaluated transmigration of melanoma cells from two different patients (M1 and M2) selected among seven melanoma primary cultures. M2 cells showed a statistically significant higher capability to pass across the in vitro BBB model, compared to M1. Expression of adhesion molecules was evaluated by flow cytometry: a statistically significant increased expression of MCAM, αvβ3, and CD49b was detected in M1. PCR array data showed that M2 had a higher expression of several matrix metalloproteinase proteins (MMPs) compared to M1. Specifically, data suggest that MMP2 and MMP9 could be directly involved in BBB permeability and that brain invasion by melanoma cells could be related to the overexpression of many MMPs. Future studies will be necessary to deepen the mechanisms of central nervous system invasion.Entities:
Mesh:
Substances:
Year: 2015 PMID: 25692137 PMCID: PMC4321090 DOI: 10.1155/2015/476069
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
Figure 1(a) The endothelial cells (E) were plated on the upper side of polycarbonate membrane at a density of 2 · 105/well and the astrocytes (A) were cultured on the bottom side of the membrane at a density of 2 · 105/well. The arrowhead shows the contact between astrocyte endfeet and endothelial cells monolayer across a pore (P) of the membrane. (b) Contact (arrowhead) between astrocyte endfeet (A) and endothelial cells (E) across a pore (P) at higher magnification. (c) Transversal section of endothelial cells monolayer (E) after four days of cocultures with astrocytes (see Material and Methods). Arrows indicate the tight junction (TJ) between two adjacent endothelial cells.
Figure 2Graphic representation of [14C]L-glucose permeability assay in our in vitro BBB model (see Material and Methods). A statistically significant decrease to L-glucose permeability was detected in cocultures after four days (-◊-) if compared to polycarbonate membrane alone (-▲-) or to HUVEC alone (-□-) plated on the upper side of the polycarbonate membrane for four days. [14C]L-Glucose permeability was expressed as ratio between the radioactivity measured in the lower chamber and the radioactivity measured in the upper chamber of the Transwell. A ratio of 1 means complete equilibrium between the upper and the lower well of the Transwell. Data are expressed as mean values ± SD (error bars) from at least three independent experiments. Statistics: in vitro BBB versus HUVEC alone (t-test).
Figure 3The panel shows the localization of two markers representative of the blood brain barrier tight junctions. (a) Expression of zonula occludens-1 (ZO-1) focalized in membrane producing a linear staining at cell boundaries and (b) merge of ZO-1 and nuclear staining (10x magnification); (B) magnification detail of ZO-1 and DAPI staining (40x magnification); (c) membrane-cytoskeletal protein of focal adhesion plaques vinculin protein; and (d) merge of vinculin and nuclear staining (10x magnification); (D) magnification detail of vinculin and DAPI staining (40x magnification). DAPI: blue; ZO-1: green; vinculin: green. Scale bar: 100 μm.
Figure 4(a) Transmigration of M1 and M2 cells across the HUVECs monolayer cocultered with astrocytes (in vitro BBB). 100.000 cells were added in the upper chamber and, after 24 hours, transmigrated cells were counted in the lower chamber (see Material end Methods). Transmigrated cells are expressed as percentage of the total number of melanoma cells used for each insert. Data are expressed as mean ± SD (error bars) from at least six independent experiments. M2 cells showed a statistically significant increased migration compared to M1 (* P = 0.000016, t-test). (b) Transmigration ability through the polycarbonate membrane alone was similar in M1 and M2 cells. 100.000 cells were loaded in the upper well of the Transwell chamber and incubated for 24 h. Data are expressed as mean percentage of the total number of cells ± SD (error bars) from at least six independent experiments.
Figure 5To exclude major differences in cell volume between M1 and M2 cells eventually accounting for the different ability to transmigrate, the forward scatter of M1 (black bar) and M2 (grey bar) cell was measured by flow cytometry. Despite M2 showing a statistically significant increased migration through the in vitro BBB compared to M1, their volume was slightly higher than that of M1 (310 versus 250 arbitrary unit) suggesting that cell volume was not responsible for the differences observed in transmigration.
Figure 6Surface adhesion molecules expression in M1 (black bars) and M2 cells (grey bars). Cultured cells were stained with the fluorochrome-conjugated specific antibody for the listed molecules and analyzed by flow cytometry (see Material and Method). Data are expressed as means ± SD (error bars) of the ratio between the mean fluorescence intensity (MFI) of specific antibody and the MFI of the relative isotypic control. Values greater than 1 indicate expression of the marker (see Material and Methods). Data refers to at least three independent experiments. Statistics: M1 versus M2 (t-test): □ P = 0.019; * P = 0.0003; ▲ P = 0.00005.
Differentially expressed genes in M1 and M2 cells as obtained by the metastasis specific real time PCR-based array (see materials and methods, Section 2). Data are expressed as fold decrease (a) or increase (b) in M2 compared to M1.
| Symbol | Gene name | Fold | Function |
|---|---|---|---|
| (a) | |||
| SYK | Spleen tyrosine kinase | −91.72 | AM |
| MCAM | Melanoma cell adhesion molecule | −29.76 | AM |
| VEGFA | Vascular endothelial growth factor A | −7.85 | AM |
| CTNNA1 | Catenin (cadherin-associated protein), alpha 1 | −6.51 | AM |
| ITGB3 | Integrin, beta 3 | −6.46 | AM |
| FAT1 | FAT atypical cadherin 1 | −5.36 | AM |
| HPSE | Heparanase | −5.05 | EMD |
| CD44 | CD44 molecule | −5.05 | AM |
| TIMP2 | Metallopeptidase inhibitor 2 | −4.72 | EMD |
| COL4A2 | Collagen, type IV, alpha 2 | −4.60 | EMD |
| APC | Adenomatous polyposis coli | −4.02 | AM |
| PNN pinin | Desmosome associated protein | −3.53 | AM |
| MMP3 | Matrix metallopeptidase 3 (stromelysin 1, progelatinase) | −2.58 | EMD |
| MTSS1 | Metastasis suppressor 1 | −2.57 | AM |
|
| |||
| (b) | |||
| CDH1 | Cadherin 1, type 1, E-cadherin | 533 | AM |
| MMP2 | Matrix metallopeptidase 2 (gelatinase A, 72 kDa gelatinase, 72 kDa type IV collagenase) | 54.35 | EMD |
| ITGA7 | Integrin, alpha 7 | 15.54 | AM |
| CDH6 | Cadherin 6, type 2, K-cadherin (fetal kidney) | 8.23 | AM |
| MMP10 | Matrix metallopeptidase 10 (stromelysin 2) | 6.83 | EMD |
| TIMP3 | TIMP metallopeptidase inhibitor 3 | 4.92 | EMD |
| CDH11 | Cadherin 11, type 2, OB-cadherin (osteoblast) | 3.97 | AM |
| MMP9 | matrix metallopeptidase 9 (gelatinase B, 92 kDa gelatinase, 92 kDa type IV collagenase) | 3.58 | EMD |
| MMP11 | Matrix metallopeptidase 11 (stromelysin 3) | 3.55 | EMD |
| MMP13 | Matrix metallopeptidase 13 (collagenase 3) | 3.31 | EMD |
| MMP7 | Matrix metallopeptidase 7 (matrilysin, uterine) | 2.61 | EMD |
| MGAT5 | Mannosyl (alpha-1,6-)-glycoprotein beta-1,6-N-acetylglucosaminyltransferase | 2.22 | AM |
| FN1 | Fibronectin 1 | 2.08 | AM |
| CTSL1 | Cathepsin L | 2.06 | EMD |